Clinical trials: Carcinoid Tumor
Cancer, Thyroid Cancer
Pharmaceutical Management in Targeted Radioligand Therapy
Targeted Radionuclide Therapy (TRT) is a treatment modality used in nuclear medicine to target cancer cells while preserving surrounding healthy tissues.
- Conditions
- Cancer, Thyroid Cancer, Metastatic Prostate Cancer, Neuroendocrine Tumor Carcinoid
- Trial name
- PharmTRT (NCT07389512)
- Where
- 3 sites in France
- Volunteers
- 600 people
- Sponsor
- Hospices Civils de Lyon
Small-intestine Neuroendocrine Tumors (Carcinoid Tumors)
Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors
Urinary measure of 5-hydroxyindolacetic acid (5HIAA) is an important marker for the diagnosis and follow-up of patients with small-intestine neuroendocrine tumors.
- Trial name
- NCT02826928
- Testing
- blood sample withdrawn
- Where
- France
- Volunteers
- 116 people
- Sponsor
- CHU de Reims
Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
An international multi-centre, open, randomised, parallel-group phase II study comparing adjuvant treatment with 177Lu-DOTATATE to best supportive care in patients after complete surgical removal of neuroendocrine liver…
- Conditions
- Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors, Liver Metastases
- Trial name
- NELMAS (NCT05987176)
- Testing
- Lutathera
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Imperial College London
Carcinoid Tumor
A Two-decade Mortality Risk Analysis of Gastrointestinal Carcinoid Neoplasms: an Updated SEER-based Study 2000-2022
Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course with the sites are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%).
- Trial name
- NCT07317713
- Volunteers
- 93,481 people
- Sponsor
- Suez Canal University
Carcinoid Tumor, SEER Database Analysis
Recent Trends in Stage Migration of Gastrointestnial Carcinoid Tumors Over Two Decades: a Retrospective SEER-based Analysis 2000-2022
Stage migration occurs when patients sound to have better survival or increased incidence rates at the early stage at diagnosis due to early detection of the disease.
- Conditions
- Carcinoid Tumor, SEER Database Analysis, Stage
- Trial name
- NCT07317726
- Volunteers
- 93,481 people
- Sponsor
- Suez Canal University
Carcinoid Tumor, Second Primary Malignant Neoplasm
The Risk of Second Primary Gastrointestinal Malignancies Following Primary Gastrointestinal Carcinoid Tumors: a SEER Based Study 2000-2022
Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course. Carcinoid tumors are the most common gastrointestinal (GI) neuroendocrine tumors.
- Trial name
- NCT07291752
- Volunteers
- 93,481 people
- Sponsor
- Suez Canal University
Neuroendocrine Tumor, Carcinoid
RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
Neuroendocrine tumors are derived from the neuroendocrine system of the gastroenteropancreatic and bronchopulmonary tract systems.
- Conditions
- Neuroendocrine Tumor, Carcinoid, Neuroendocrine Carcinoma
- Trial name
- RegisterNET (NCT02270567)
- Testing
- NETest
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Wren Laboratories LLC
Advanced Cancer, Anal Carcinoma
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
- Conditions
- Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer
- Trial name
- NCT02628067
- Testing
- pembrolizumab
- Volunteers
- 1,609 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
ALG-LungCancerRegistry (SAFRO2202)
SAFRO 2202 ALG-Lung Cancer Registry is a prospective, multicenter, non-interventional observational study conducted across 21 public and university hospitals in Algeria.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Carcinoid Tumor
- Trial name
- SAFRO2202 (NCT07161882)
- Testing
- Observational Data Collection
- Where
- 21 sites in Algeria
- Volunteers
- 3,750 people
- Sponsor
- Société Algérienne de Formation et de Recherche en Oncologie
Carcinoid Tumor Lung, Neuroendocrine Tumor of the Lung
A Safety Study of 212Pb-Pentixather Radioligand Therapy
This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (Lead-212 labelled Pentixather) in patients who have been diagnosed with, and previously treated, for atypical carcinoid lesions of the…
- Conditions
- Carcinoid Tumor Lung, Neuroendocrine Tumor of the Lung, Carcinoma, Small-Cell Lung
- Trial name
- NCT05557708
- Testing
- 212-Lead Pentixather, 203-Lead Pentixather SPECT/CT
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yusuf Menda
Midgut Carcinoid Tumor, Biliary Stones
Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.
The investigators want to study the effectiveness of prophylactic cholecystectomy in patients with midgut neuroendocrine tumor (jejunum, ileum or proximal colon) who require primary tumor surgery.
- Trial name
- TNE-IDC-COLE (NCT04735198)
- Testing
- Primary tumor surgery, Primary tumor surgery (bowel resection) combined with prophylactic cholecystectomy
- Where
- 6 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Hospital Universitari de Bellvitge
Neuroendocrine (NE) Tumors, Neuroendocrine Tumor GEP Grade 1-3
Life Following Excision of Neuroendocrine Tumors
Neuroendocrine tumors (NETs), often seen as "chronic cancer" present a survival paradox with relatively prolonged patient survival despite active disease.
- Trial name
- LIFENETS (NCT06981455)
- Where
- Canada
- Volunteers
- 246 people
- Sponsor
- Sunnybrook Health Sciences Centre
Appendix Cancer, Appendiceal Cancer
Genetics of Appendix Cancer Study
The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individuals diagnosed with appendix/appendiceal cancer who are ages 18+ years.
- Conditions
- Appendix Cancer, Appendiceal Cancer, Appendiceal Neoplasms, Appendiceal Mucinous Neoplasm
- Trial name
- GAP (NCT05734430)
- Testing
- Genetic profiling, Retrospective tissue procurement
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Andreana Holowatyj, PhD, MSCI
Carcinoid Syndrome, Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
This pilot trial studies how well telotristat etiprate works in treating participants with well differentiated neuroendocrine neoplasm that has spread to other places in the body and monitored by carbon C 11…
- Trial name
- NCT03453489
- Testing
- Carbon C 11 Alpha-methyltryptophan, Laboratory Biomarker Analysis, Positron Emission Tomography
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Carcinoid Tumors
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.
- Trial name
- NCT02795858
- Testing
- Ramucirumab, Somatostatin Analog
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Dana-Farber Cancer Institute
Carcinoid Tumor, Carcinoid Tumor of GI System
Cabozantinib and Nivolumab for Carcinoid Tumors
This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the…
- Conditions
- Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors
- Trial name
- NCT04197310
- Testing
- Nivolumab, Cabozantinib
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Gastroenteropancreatic Neuroendocrine Tumors
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
The purpose of the study was to evaluate the effect of arginine/lysine solution administration on serum potassium levels. A systematic assessment of serum potassium levels was performed during infusion and up to 24 hours post…
- Trial name
- NCT04524442
- Testing
- arginine/lysine
- Where
- 7 sites in Italy, Netherlands and 2 more
- Volunteers
- 42 people
- Sponsor
- Advanced Accelerator Applications
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Neoplasms, Neoplasm Metastasis
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.
- Conditions
- Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT05176665
- Testing
- EMB-01
- Where
- 14 sites in United States, China
- Volunteers
- 152 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Gastrinoma, Glucagonoma
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00655655
- Testing
- everolimus, vatalanib, pharmacological study
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic